Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending September 23, 2015. The report disseminates a press release from ViiV Healthcare Ltd, a global specialist HIV company in which GSK is a shareholder alongside Pfizer and Shionogi. The filing focuses on clinical trial data rather than GSK's consolidated financial results.
Key Financial Metrics
The filing text does not provide a clear value for GSK's revenue, profit, cash flow, margins, debt, or liquidity. This document is a current report regarding a specific clinical study update and does not contain financial statements or performance metrics for the registrant.
Material Changes and Clinical Data
The primary material update concerns the Phase IIIb/IV STRIIVING study evaluating the switch to Triumeq (abacavir/dolutegravir/lamivudine) in virologically suppressed adults with HIV-1.
- Study Population: 551 total participants (274 switched to Triumeq; 277 remained on existing ART).
- Primary Endpoint: Viral suppression (HIV RNA <50 copies/mL) at 24 weeks was non-inferior for the switch group (85%) compared to the existing ART group (88%).
- Per Protocol Analysis: Viral suppression was 93% for both groups.
- Virologic Failure: No patients in either arm experienced protocol-defined virologic failure.
- Patient Satisfaction: Treatment satisfaction scores improved significantly more for patients switching to Triumeq (adjusted difference 2.4, p<0.001).
- Adverse Events: Withdrawal due to adverse events was higher in the switch group (4%) compared to the existing ART group (0%). Common adverse events in the switch group included nausea (10%), diarrhea (7%), fatigue (7%), and upper respiratory tract infection (7%).
Outlook, Risks, and Contingencies
Management commentary from ViiV Healthcare's Chief Scientific and Medical Officer suggests these data support Triumeq as a treatment option for switching patients, balancing efficacy with tolerability and dosing convenience.
Material Risks and Safety Information:
- Hypersensitivity: Serious and sometimes fatal hypersensitivity reactions are associated with abacavir. Patients with the HLA-B*5701 allele are at high risk and must not take Triumeq.
- Hepatic Risks: Risks include lactic acidosis, severe hepatomegaly, and exacerbations of Hepatitis B upon discontinuation of lamivudine.
- Drug Interactions: Co-administration with dofetilide is contraindicated. Interactions with other drugs may alter concentrations.
- Forward-Looking Statements: GSK cautions that projections are subject to risks and uncertainties that may cause actual results to differ materially.
Investor Verification Checklist
- Verify the commercial impact of the STRIIVING study results on Triumeq sales projections.
- Review the full prescribing information for Triumeq regarding contraindications, specifically the HLA-B*5701 allele screening requirement.
- Assess the competitive landscape for once-daily HIV regimens following this non-inferiority data.
- Monitor for any future safety signals regarding the 4% withdrawal rate due to adverse events in the switch population.
- Confirm GSK's ownership stake and financial reporting structure regarding ViiV Healthcare in subsequent 20-F filings.